Recent Updates
Recently added Catalysts
REGN

REGENERON’S AXOKINE PROMOTES WEIGHT LOSS IN STUDY OF OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES

Wednesday, April 16, 2003 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: REGENERON’S AXOKINE PROMOTES WEIGHT LOSS IN STUDY OF OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema

Full Press Release Details

REGENERON’S AXOKINE PROMOTES WEIGHT LOSS IN STUDY OF OVERWEIGHT AND OBESE PEOPLE WITH TYPE 2 DIABETES.
ShareAdd on Google
Tags: REGN Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Apr 16, 2003

Biotech snapshot

Cash runway
$17823M liquidity · $0M/mo burn
Low dilution risk
Lead asset
VEGF Trap-EyePhase 1
Diabetic Macular Edema →

Catalyst track record

+35%
best trade around REGN's most recent catalyst

Peak hindsight return over a 120-day window, across 15 tracked FDA/PDUFA catalysts for REGN.

See every catalyst's timing & PoA →